Why Some Telehealth Platforms Offer Brand-Name Only (And Why You Might Want That)

Most of the GLP-1 telehealth market runs on compounded semaglutide and tirzepatide. A smaller, growing segment only prescribes FDA-approved brand-name medications: Wegovy, Zepbound, Ozempic, and Mounjaro. The brand-name-only providers are often more expensive. They are also operating on fundamentally firmer regulatory ground. For the right patient, the trade is worth it.

This piece explains why the brand-name-only model exists, who it fits, and how to think about the cost difference.

The regulatory distinction

FDA-approved brand-name GLP-1 medications are manufactured by Novo Nordisk (semaglutide: Wegovy for weight management, Ozempic for Type 2 diabetes) and Eli Lilly (tirzepatide: Zepbound for weight management, Mounjaro for Type 2 diabetes). Each has been through the full FDA approval pathway: preclinical testing, Phase 1-3 trials, New Drug Application, and ongoing post-market safety monitoring.

Compounded semaglutide and tirzepatide are produced by 503A compounding pharmacies. They are not FDA-approved products. They exist under a specific statutory allowance that permits compounding when a drug is on the FDA shortage list or when a licensed clinician determines a specific patient needs a customized formulation.

The shortage allowances for semaglutide and tirzepatide have evolved significantly since 2023. FDA has removed both from their shortage lists at various points, which triggers changes in what 503A pharmacies can produce. The landscape is fluid. A telehealth provider that relies on compounded product is operating in a regulatory environment that can change.

A brand-name-only provider is immune to most of this volatility. The product they prescribe is manufactured by an FDA-regulated pharmaceutical company with decades of quality systems. The supply chain runs through standard pharmacy distribution. The labeling, dosing, storage, and shelf life are all well-established and regulated.

Why brand-name costs more

Brand-name GLP-1s are priced at a premium. The U.S. list price for Wegovy and Zepbound is in the $1,000-$1,350 per month range before insurance. Ozempic and Mounjaro are similar. Savings cards, manufacturer programs, and insurance coverage can bring the effective cost down substantially — but the out-of-pocket cash price without insurance is high.

Compounded semaglutide and tirzepatide, by contrast, are typically priced at $200-$450/month depending on the provider, dose, and pharmacy. The cost gap is real and large.

Brand-name-only platforms address this in several ways:

• Insurance optimization. They help patients navigate coverage, prior authorizations, and appeals.
• Manufacturer savings cards. Eli Lilly and Novo Nordisk both offer savings programs. The specifics change periodically, but for insured patients with coverage, out-of-pocket can be reduced significantly.
• Cash-pay programs. Some platforms have negotiated cash-pay rates directly with the manufacturers, available at specific subscription tiers.

Who is brand-name-only right for?

This model is a particularly good fit for a few patient profiles:

Patients whose insurance covers GLP-1s

If your insurance covers Wegovy or Zepbound with a reasonable copay, brand-name through a telehealth platform that files insurance is often the cheapest total solution. Plus you get the regulatory certainty of FDA-approved product.

Patients uncomfortable with compounding

Some patients have considered the options and concluded they want the product that went through the FDA approval pathway. This is a reasonable preference, especially for people with complex medical histories who place high value on the evidence base from pivotal trials.

Patients with specific medical considerations

For certain patients — complicated drug interactions, unusual contraindications, specific GI conditions — the ability to reference extensive labeling, prescribing information, and post-market safety data for an FDA-approved product is meaningful. Compounded formulations don't have the same level of documentation.

Patients planning to stay on long-term

Regulatory certainty matters more on a long horizon. If you plan to be on a GLP-1 for years, the chance of a disruptive regulatory event affecting compounding is higher than if you're on for six months. Brand-name-only provides continuity.

Who is brand-name-only NOT right for?

Two patient profiles where compounded may be the better fit:

Uninsured patients facing acute affordability

If you have no coverage, a savings card doesn't apply, and you can't comfortably budget $800+/month, compounded is often the only feasible path to GLP-1 therapy. That's a real-world reality, and it's why compounded telehealth has a legitimate place in the market despite its regulatory volatility.

Patients comfortable with the tradeoffs

Plenty of informed patients have evaluated compounded versus brand-name and chosen compounded, fully understanding the regulatory and supply-chain differences. That's a reasonable choice when made with eyes open.

Brand-name-only platforms: what to look for

Not all brand-name-only providers operate the same way. When evaluating:

The cost calculation, honestly

For someone with insurance coverage that applies to GLP-1s:

• Wegovy or Zepbound with a $50 copay after insurance: $50/month
• Manufacturer savings card on top (if eligible): further reduction, varies
• Brand-name platform consultation fee: $50-$100 per visit, less frequent after stable
• Effective monthly cost: often under $200/month

For someone without insurance coverage for GLP-1s:

• Manufacturer cash-pay program (where available): $499/month currently for eligible products
• Platform consultation fee: $50-$100 per visit
• Effective monthly cost: $550-$650/month

Compared to compounded at $250-$400/month, the price gap exists but is narrower than the list prices suggest. For insured patients, brand-name is often actually cheaper. For uninsured patients, compounded is cheaper in absolute dollars but comes with the regulatory and supply-chain caveats.

A practical decision framework

1. Check your insurance coverage for GLP-1s first. If covered with a reasonable copay, brand-name-only is almost certainly your best option.
2. If uninsured, check manufacturer savings cards and cash-pay programs. The numbers move; keep checking.
3. Weight long-term plans. The longer you expect to be on therapy, the more regulatory certainty pays off.
4. Factor in your tolerance for regulatory uncertainty. Some people are comfortable with compounding; others are not. Both are valid.
5. Evaluate providers on the full checklist (see our 12-Point Legitimacy Checklist) — brand-name-only alone doesn't make a provider good.

The bottom line

Brand-name-only is not a luxury tier. It's a different regulatory model with different tradeoffs. For insured patients, it's often the cheapest total solution. For patients who place high value on FDA-approved product or plan to be on therapy long-term, the cost premium (where it exists) buys genuine risk reduction. For patients facing acute affordability with no insurance, compounded has a legitimate role.

The worst choice is not knowing which model you're on. Once you understand the difference, the answer for your situation usually becomes clear.